Chemokine receptor modulators and uses thereof

1. A method of treating a disease or disorder, wherein the disease or disorder is cancer, an immune disease or disorder, an inflammatory disease or disorder, a cardiovascular disease or disorder, or a metabolic disease or disorder, comprising administering to a subject suffering from said disease or disorder a therapeutically effective amount of a C—C chemokine receptor type 4 (CCR4) inhibitor, wherein the CCR4 inhibitor is of structural Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

X 2 is CR 9 or N;

X 3 is CR 10 or N;

n3.2, n3.3, n9 and n10 are independently an integer from 0 to 4;

m3.2, m3.3, m9, m10, v3.2, v3.3, v9 and v10 are independently 1 or 2 z4 is 1;

L 7 is a bond, —O—, —S—, —NR 7.2B —, —C(O)—, —C(O)O—, —S(O)—, —S(O) 2 —, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

R 1 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;

R 2 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;

R 3.2 is hydrogen, halogen, —CX 3.2 3 , —CHX 3.2 2 , —CH 2 X 3.2 , —CN, —N 3 , —SO n3.2 R 3.2A , —SO v3.2 NR 3.2B R 3.2C , —NHNR 3.2B R 3.2C , —ONR 3.2B R 3.2C , —NHC(O)NHNR 3.2B R 3.2C , —NHC(O)NR 3.2B R 3.2C , —N(O) m3.2 , —NR 3.2B R 3.2C , —C(O)R 3.2D , —C(O)OR 3.2D , —C(O)NR 3.2B R 3.2C , —OR 3.2A , —NR 3.2B SO 2 R 3.2A , —NR 3.2B C(O)R 3.2D , —NR 3.2B C(O)OR 3.2D , —NR 3.2B OR 3.2D , —OCX 3.2 3 , —OCHX 3.2 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 3.3 is hydrogen, halogen, —CX 3.3 3 , —CHX 3.3 2 , —CH 2 X 3.3 , —CN, —N 3 , —SO n3.3 R 3.3A , —SO v3.3 NR 3.3B R 3.3C , —NHNR 3.3B R 3.3C , —ONR 3.3B R 3.3C , —NHC(O)NHNR 3.3B R 3.3C , —NHC(O)NR 3.3B R 3.3C , —N(O) m3.3 , —NR 3.3B R 3.3C , —C(O)R 3.3D , —C(O)OR 3.3D , —C(O)NR 3.3B R 3.3C , —OR 3.3A , —NR 3.3B SO 2 R 3.3A , —NR 3.3B C(O)R 3.3D , —NR 3.3B C(O)OR 3.3D , —NR 3.3B OR 3.3D , —OCX 3.3 3 , —OCHX 3.3 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is hydrogen, —CX 4.1 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;

R 7 is hydrogen, substituted or unsubstituted alkyl, phenyl, —F, —OH, CH 2 OH, —(CH 2 ) 2 OH, —(CH 2 ) 3 OH, —C(CH 3 ) 2 OH, —CH 2 SO 2 NH 2 , —(CH 2 ) 2 SO 2 NH 2 , —CH 2 C(O)NH 2 , —(CH 2 ) 2 C(O)NH 2 , —(CH 2 ) 3 C(O)NH 2 , —CH 2 NHSO 2 CF 3 , —(CH 2 ) 2 NHSO 2 CF 3 , —(CH 2 ) 3 NHSO 2 CF 3 , —CH 2 NHSO 2 CH 3 , —(CH 2 ) 2 NHSO 2 CH 3 , —(CH 2 ) 3 NHSO 2 CH 3 , —CH 2 SO 2 CH 3 , —(CH 2 ) 2 SO 2 CH 3 , —CH 2 SO 2 NH 2 or —(CH 2 ) 2 SO 2 NH 2 ;

R 9 is hydrogen, halogen, —CX 9.1 3 , —CHX 9.1 2 , —CH 2 X 9.1 , —CN, —N 3 , —SO n9 R 9A , —SO v9 NR 9B R 9C , —NHNR 9B R 9C , —ONR 9B R 9C , —NHC(O)NHNR 9B R 9C , —NHC(O)NR 9B R 9C , —N(O) m9 , —NR 9B R 9C , —C(O)R 9D , —C(O)OR 9D , —C(O)NR 9B R 9C , —OR 9A , —NR 9B SO 2 R 9A , —NR 9B C(O)R 9D , —NR 9B C(O)OR 9D , —NR 9B OR 9D , —OCX 9.1 3 , —OCHX 9.1 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 10 is hydrogen, halogen, —CX 10.1 3 , —CHX 10.1 2 , —CH 2 X 10.1 , —CN, —N 3 , —SO n10 R 10A , —SO v10 NR 10B R 10C , —NHNR 10B R 10C , —ONR 10B R 10C , —NHC(O)NHNR 10B R 10C , —NHC(O)NR 10B R 10C , —N(O) m10 , —NR 10B R 10C , —C(O)R 10D , —C(O)OR 10D , —C(O)NR 10B R 10C , —OR 10A , —NR 10B SO 2 R 10A , —NR 10B C(O)R 10D , —NR 10B C(O)OR 10D , —NR 10B OR 10D , —OCX 10.1 3 , —OCHX 10.1 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 3.2A , R 3.2B , R 3.2C , R 3.2D , R 3.3A , R 3.3B , R 3.3C , R 3.3D , R 9A , R 9B , R 9C , R 9D , R 10A , R 10B , R 10C and R 10D are independently hydrogen, halogen, —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —COOH, —CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3.2B , R 3.2C , R 3.3B , R 3.3C , R 9B , R 9C , R 10B , and R 10C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; and

X 3.2 , X 3.3 and X 4.1 are independently —Cl, —Br, —I or —F.

2. The method of claim 1 , wherein the compound has structural Formula (IIa):

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound has structural Formula (IIb):

or a pharmaceutically acceptable salt thereof.

4. The method of claim 2 , wherein the compound has structural Formula (IIc):

or a pharmaceutically acceptable salt thereof.

5. The method of claim 3 , wherein the compound has structural Formula (IId):

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein R 1 is hydrogen.

7. The method of claim 1 , wherein R 2 is substituted or unsubstituted alkyl.

8. The method of claim 1 , wherein R 4 is —CN, —C(O)NH 2 , —CF 3 or —CH 3 .

9. The method of claim 1 , wherein R 3.2 and R 3.3 are independently halogen.

10. The method of claim 1 , wherein:

L 7 is a bond; and

R 7 is hydrogen, substituted or unsubstituted alkyl, phenyl, —(CH 2 ) 2 OH, —CH 2 C(CH 3 ) 2 OH, —(CH 2 ) 3 OH, —(CH 2 ) 2 CH(CH 3 ) 2 OH, —(CH 2 ) 2 SO 2 NH 2 , —(CH 2 ) 3 SO 2 NH 2 , —(CH 2 ) 2 CONH 2 , —(CH 2 ) 3 CONH 2 —(CH 2 ) 3 CON(H)Me, —(CH 2 ) 3 CON(Me) 2 , —(CH 2 ) 2 SO 2 Me, —(CH 2 ) 3 SO 2 Me, —CH 2 CH(OH)Me, —CH 2 CO 2 H, —(CH 2 ) 2 CO 2 H, —CH(CH 3 )CH 2 CO 2 H, —(CH 2 ) 3 CO 2 H, —(CH 2 ) 2 SO 2 NHCH 3 , —(CH 2 ) 2 SO 2 N(CH 3 ) 2 , —(CH 2 ) 2 SO 2 —(N-morpholinyl), —(CH 2 ) 2 NHCOCH 3 , —(CH 2 ) 3 NHCOCH 3 , —(CH 2 ) 2 NHCOCH(CH 3 ) 2 , —(CH 2 ) 2 NHSO 2 CH 3 , —(CH 2 ) 2 NHSO 2 CF 3 , —(CH 2 ) 2 NHSO 2 NHCH(CH 3 ) 2 , —CH 2 CH(CH 3 )CH 2 OH (R and S), —CH(CH 3 )(CH 2 ) 2 OH, —CH 2 -(2-imidazoyl), —CH 2 -(4-imidazoyl), —CH 2 -(3-pyrazoyl), 4-tetrahydropyranyl, 3-oxetanyl, —(CH 2 ) 2 NHCO 2 Me, —(CH 2 ) 3 NHCO 2 Me.

11. The method of claim 1 , wherein the compound has structural Formula (IV):

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound has structural Formula (V):

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the compound has the structure:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 , further comprising co-administering a chemotherapeutic agent or anticancer agent in combination with the compound of structural Formula (II).

15. The method of claim 14 , wherein the chemotherapeutic agent or anticancer agent is an antiproliferative/antineoplastic drug, an antimetabolite, an antitumour antibiotic, an antimitotic agent, a topoisomerase inhibitor, a cytostatic agent, an oestrogen receptor down regulator, an antiandrogen, a LHRH antagonist or LHRH agonist, a progestogen, an aromatase inhibitor, an inhibitor of 5.alpha.-reductase, an agent which inhibits cancer cell invasion, an inhibitor of growth factor function, a farnesyl transferase inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family, an inhibitor of the platelet-derived growth factor family, an inhibitor of the hepatocyte growth factor family; an antiangiogenic agent, a vascular damaging agent, an agent used in antisense therapy, an anti-ras antisense, an agent used in a gene therapy, an immunotherapeutic agent, or an antibody.

16. The method of claim 15 , further comprising co-administering a therapeutically effective amount of at least two of: a CCR4 inhibitor, an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4 or an agonistic antibody of CD137 (4-1BB).

17. The method of claim 15 , further comprising co-administering a therapeutically effective amount of at least two of: a CCR4 inhibitor, an immunotherapeutic agent or an agent selected from a checkpoint-receptor, a cytokine, a kinase, an epigenetic regulator, a transcription regulator, a signaling molecule, a pathogene recognition receptor, a chemokine, an adhesion molecule, an immune receptor ligand, a checkpoint ligand, a nucleoside, and ecto-enzyme, an enzyme, an endo/ecto enzyme, a transcription factor, and an TNF superfamily member, or any combination thereof.

18. The method of claims 1 or 14 , wherein the cancer is colon cancer, pancreatic cancer, kidney cancer, breast cancer, lung cancer, bladder cancer, urinary bladder cancer, ovarian cancer, endometrial cancer, adrenal cortical cancer, cervical cancer, prostate cancer, stomach cancer, gastric cancer, colorectal cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, glioma, esophagus cancer, esophageal cancer, liver cancer, genitourinary tract cancer, lymphoma, leukemia, cancer of the thyroid, medullary thyroid cancer, papillary thyroid cancer, or cancer of the endocrine system.

19. The method of claim 18 , wherein the cancer is hepatocarcinoma, B-acute lymphoblastic lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, Small Cell lymphoma, Large Cell lymphomas, classical Hodgkin's lymphoma, MDS, AML, ALL, ATLL, CML, multiple myeloma, glioblastoma, neuroblastoma, non-small cell lung cancer, melanoma, mesothelioma, medulloblastoma, thyroid carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, skin cutaneous melanoma, colon adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, breast invasive carcinoma, triple-negative breast cancer, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's Disease, neuroblastoma, glioblastoma multiforme, rhabdomyosarcoma, primary brain tumos, malignant pancreatic insulanoma, malignant carcinoid, premalignant skin lesions, neuroblastoma, malignant hypercalcemia, neoplasms of the endocrine or exocrine pancreas, medullary thyroid carcinoma, melanoma, or hepatocellular carcinoma.

20. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

21. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

22. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

23. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

24. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

25. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.